查看購物車
  • Simplified Chinese
  • English
封面
市場調查報告書
商品編碼
1830992

多囊性卵巢症候群（PCOS）治療市場

Polycystic Ovarian Syndrome (PCOS) Treatment Market
出版日期: | 出版商: The Insight Partners | 英文 150 Pages | 商品交期: 1-5個工作天內

價格
簡介目錄

多囊性卵巢症候群 (PCOS) 治療市場預測有助於利害關係人制定成長策略。預計該市場規模將從 2024 年的 39.8 億美元增至 2031 年的 52.6 億美元，2025 年至 2031 年的複合年成長率估計為 5.4%。全球 PCOS 盛行率的上升，以及 PCOS 治療醫療支出的顯著成長，是推動多囊性卵巢症候群 (PCOS) 治療市場成長的關鍵因素。例如，美國約有 600 萬名女性患有 PCOS，這是一種常見的荷爾蒙失調疾病，會增加子宮內膜癌、高血壓、2 型糖尿病、不孕症和中風等各種健康問題的風險。此外，美國內分泌學會預測，PCOS 是育齡女性中最常見的荷爾蒙失調疾病，2020 年其診斷和治療將在美國產生 80 億美元的全國性費用。

預計在預測期內，創新療法的發展將為多囊性卵巢症候群 (PCOS) 治療市場帶來新的趨勢。

成長動力：全球女性多囊性卵巢症候群 (PCOS) 發生率上升推動多囊性卵巢症候群 (PCOS) 治療市場的成長多囊性卵巢症候群 (PCOS) 是一種影響女性的廣泛多因子內分泌疾病。世界衛生組織 (WHO) 估計，PCOS 影響約 8-13% 的育齡婦女。它是導致無排卵的主要原因，也是全球不孕症的重要因素。此外，約 70% 的多囊性卵巢症候群女性仍未被診斷出來。不健康飲食和某些環境影響等因素會導致 PCOS 的發病。肥胖是重要的風險因素，因為超重會破壞荷爾蒙平衡和胰島素敏感性，從而導致病情發展。隨著全球肥胖危機的加劇，越來越多的女性面臨 PCOS 的風險。根據世界肥胖聯合會發布的《2022年世界肥胖地圖集》，到2030年，全球將有超過10億人受到肥胖的影響，其中包括五分之一的女性。

此外，多囊性卵巢症候群 (PCOS) 發病率的不斷上升也導致了對有效治療方案的需求日益成長。目前已有多種藥物和非藥物療法可用於調節荷爾蒙水平、增強胰島素敏感性以及解決其他與 PCOS 相關的潛在問題。因此，全球女性 PCOS 盛行率的不斷上升是多囊性卵巢症候群 (PCOS) 治療市場成長的重要驅動力。

限制：FDA 批准的 PCOS 藥物供應有限，阻礙了多囊性卵巢症候群 (PCOS) 治療市場的發展。 FDA 批准的專門用於治療與多囊性卵巢症候群 (PCOS) 相關的複雜症狀和荷爾蒙失衡的藥物供應有限。儘管 PCOS 盛行率高，並且對女性健康、生育能力和生活品質造成巨大影響，但 FDA 批准的治療這種疾病的藥物選擇相對較少（通常是超說明書用藥）。 FDA 批准藥物的稀缺性給尋求有效、循證 PCOS 治療的醫療保健提供者和患者帶來了挑戰。雖然超說明書用藥某些藥物（如口服避孕藥、胰島素增敏劑和抗雄性激素藥物）在治療 PCOS 症狀方面很常見，但缺乏專門的治療方法限制了綜合治療方案。因此，FDA 批准的專門針對 PCOS 的藥物有限阻礙了多囊性卵巢症候群 (PCOS) 治療市場的成長。

策略洞察報告細分和範圍：透過檢查以下細分市場對多囊性卵巢症候群 (PCOS) 治療市場進行分析：產品和配銷通路。

依產品分類，多囊性卵巢症候群 (PCOS) 治療市場分為克羅米芬檸檬酸鹽、二甲雙胍、吡格列酮、口服避孕藥等。二甲雙胍在 2023 年佔據最大市場佔有率，而克羅米芬檸檬酸鹽預計在預測期內將呈現最高的複合年成長率。

從配銷通路來看，多囊性卵巢症候群 (PCOS) 治療市場分為醫院藥房、零售藥房和線上藥房。 2023 年，醫院藥局佔據多囊性卵巢症候群 (PCOS) 治療市場的最大佔有率，預計在預測期內將實現最高的複合年成長率。

區域分析：從地理上講，多囊性卵巢症候群 (PCOS) 治療市場報告的範圍包括北美、歐洲、亞太地區、南美和中美以及中東和非洲。 2023 年，北美佔據了最大的市場佔有率。先進醫療器材技術的日益普及、PCOS 盛行率的上升以及主要參與者的持續產品創新，促進了北美多囊性卵巢症候群 (PCOS) 治療市場的成長。根據美國衛生與公共服務部的數據，PCOS 是美國女性不孕症的常見原因，影響約 6% 至 12%（約 500 萬）的育齡婦女。 2023 年 7 月發表在《美國婦產科雜誌》上的一項研究報告稱，美國每年每 10,000 人中有 42.5 例 PCOS 發病率。此外，該國各組織致力於全面評估、提高意識並專注於與 PCOS 相關的研究。例如，加州大學舊金山分校生殖健康中心積極參與研究，以了解多囊性卵巢症候群 (PCOS) 的病因。因此，PCOS 的高盛行率以及專注於研究和提高認知度的機構的存在，推動了多囊性卵巢症候群 (PCOS) 治療市場的成長。

多囊性卵巢症候群 (PCOS) 治療市場報告範圍產業發展與未來機會：正如公司新聞稿所報導的，多囊性卵巢症候群 (PCOS) 治療市場主要參與者的幾項策略發展重點如下：

2023年4月，Celmatix啟動了一項新的PCOS藥物項目，推出了其最新的針對中樞神經系統(CNS)外褪黑激素受體的治療方案。該治療方法旨在填補針對各種女性健康問題的有效一線療法的巨大市場空白，這些問題首先是PCOS，並可能擴展到子宮內膜異位症和更年期症狀。 2022年1月，Celmatix公司宣布與Evotec公司為期五年的多標靶合作取得了里程碑式的成果。 Evotec 和拜耳公司達成了一項里程碑，將以 Celmatix 確定的新藥物標靶為重點的 PCOS 藥物計劃推進到命中確定階段。競爭格局與關鍵公司：多囊性卵巢症候群 (PCOS) 治療市場報告中介紹的知名公司包括賽諾菲公司、默克公司、諾華公司、邁蘭公司、武田製藥有限公司、雅培公司、梯瓦製藥公司、Salix Pharmaceuticals Inc、阿斯利康公司和輝瑞公司。這些公司致力於開發新技術、改進現有產品並擴大其地理覆蓋範圍，以滿足日益成長的全球消費者需求。

目錄

第1章：簡介

第2章：執行摘要

  • 關鍵見解
  • 市場吸引力分析

第3章：研究方法

第4章：多囊性卵巢症候群（PCOS）治療市場格局

  • 概述
  • PEST分析

第5章：多囊性卵巢症候群（PCOS）治療市場－關鍵市場動態

  • 關鍵市場促進因素
  • 主要市場限制因素
  • 關鍵市場機會
  • 未來趨勢
  • 促進因素和限制因素的影響分析

第6章：多囊性卵巢症候群（PCOS）治療市場 - 全球市場分析

  • 多囊性卵巢症候群（PCOS）治療－全球市場概覽
  • 多囊性卵巢症候群 (PCOS) 治療 - 全球市場及 2031 年預測

第7章：多囊性卵巢症候群（PCOS）治療市場-收入分析-按產品，2021-2031

  • 概述
  • 克羅米芬檸檬酸鹽
  • 二甲雙胍
  • 吡格列酮
  • 口服避孕藥
  • 其他

第 8 章：多囊性卵巢症候群 (PCOS) 治療市場 - 收入分析 - 按配銷通路，2021-2031 年

  • 概述
  • 醫院藥房
  • 零售藥局
  • 網路藥局

第9章：多囊性卵巢症候群（PCOS）治療市場－收入分析，2021-2031－地理分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 英國
    • 歐洲其他地區
  • 亞太
    • 澳洲
    • 中國
    • 印度
    • 日本
    • 韓國
    • 亞太其他地區
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 中東和非洲其他地區
  • 南美洲和中美洲
    • 巴西
    • 阿根廷
    • 南美洲和中美洲其他地區

第10章：產業格局

  • 併購
  • 協議、合作、合資企業
  • 新產品發布
  • 擴張和其他策略發展

第 11 章：競爭格局

  • 關鍵參與者的熱圖分析
  • 公司定位與集中度

第 12 章：多囊性卵巢症候群 (PCOS) 治療市場 - 主要公司簡介

  • Sanofi SA
  • Merck KGaA
  • Novartis
  • Mylan
  • Takeda Pharmaceutical Company Ltd
  • Abbott
  • Teva Pharmaceuticals
  • Salix Pharmaceuticals
  • AstraZeneca
  • Pfizer Inc

第 13 章：附錄

簡介目錄
Product Code: TIPRE00004072

The forecast for the polycystic ovarian syndrome (PCOS) treatment market assists stakeholders in formulating their growth strategies. The market is expected to expand from US$ 3.98 billion in 2024 to US$ 5.26 billion by 2031, with an estimated CAGR of 5.4% from 2025 to 2031.The rising global prevalence of PCOS, along with a notable increase in healthcare expenditures on PCOS treatments, are key factors driving the growth of the polycystic ovarian syndrome (PCOS) treatment market. For example, around 6 million women in the US are affected by PCOS, a prevalent hormonal disorder that elevates the risk of various health issues, including endometrial cancer, hypertension, type 2 diabetes, infertility, and stroke. Additionally, the Endocrine Society projects that the diagnosis and treatment of PCOS, the most common hormonal disorder among women of reproductive age, will incur a national cost of US$ 8 billion in 2020.

The development of innovative therapeutics is expected to introduce new trends in the polycystic ovarian syndrome (PCOS) treatment market during the forecast period.

Growth Drivers:Rising Global Incidence of PCOS Among Women Fuels Growth in the Polycystic Ovary Syndrome (PCOS) Treatment Market

Polycystic ovary syndrome (PCOS) is a widespread multifactorial endocrine disorder affecting women. The World Health Organization (WHO) estimates that PCOS impacts approximately 8-13% of women of reproductive age. It is the leading cause of anovulation and a significant contributor to infertility worldwide. Furthermore, about 70% of women with PCOS remain undiagnosed. Factors such as unhealthy diets and certain environmental influences can lead to the onset of PCOS. Obesity is a significant risk factor, as excess body weight can disrupt hormonal balance and insulin sensitivity, contributing to the condition's development. With the global obesity crisis escalating, more women are at risk of developing PCOS. According to the World Obesity Federation's 2022 World Obesity Atlas, over one billion people globally will be affected by obesity by 2030, including one in five women.

Moreover, the increasing incidence of PCOS has resulted in a heightened demand for effective treatment options. A variety of pharmaceutical and non-pharmaceutical treatments are available to help regulate hormone levels, enhance insulin sensitivity, and address other underlying issues related to PCOS. Therefore, the growing prevalence of PCOS among women worldwide is a significant driver of the polycystic ovarian syndrome (PCOS) treatment market's growth.

Restraint:Limited Availability of FDA-Approved Medications for PCOS Impedes the Polycystic Ovarian Syndrome (PCOS) Treatment Market

The availability of FDA-approved medications specifically designed to treat the complex symptoms and hormonal imbalances associated with polycystic ovary syndrome (PCOS) is limited. Despite the high prevalence of PCOS and its considerable impact on women's health, fertility, and quality of life, there are relatively few FDA-approved pharmaceutical options (often off-label) for treating this condition. This scarcity of FDA-approved medications poses challenges for healthcare providers and patients seeking effective, evidence-based treatments for PCOS. While off-label use of certain medications, such as oral contraceptives, insulin-sensitizing agents, and anti-androgens, is common in managing PCOS symptoms, the lack of dedicated therapies restricts comprehensive treatment options. Consequently, the limited availability of FDA-approved medications specifically for PCOS hinders the growth of the polycystic ovarian syndrome (PCOS) treatment market.

Strategic Insights

Report Segmentation and Scope:The analysis of the polycystic ovarian syndrome (PCOS) treatment market has been conducted by examining the following segments: product and distribution channel.

By product, the polycystic ovarian syndrome (PCOS) treatment market is divided into clomiphene citrate, metformin, pioglitazone, oral contraceptives, and others. The metformin segment accounted for the largest market share in 2023, while the clomiphene citrate segment is expected to exhibit the highest CAGR during the forecast period.

In terms of distribution channel, the polycystic ovarian syndrome (PCOS) treatment market is categorized into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held the largest share of the polycystic ovarian syndrome (PCOS) treatment market in 2023 and is projected to register the highest CAGR during the forecast period.

Regional Analysis:Geographically, the scope of the polycystic ovarian syndrome (PCOS) treatment market report includes North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa. In 2023, North America held the largest market share. The increasing adoption of advanced medical device technologies, the rising prevalence of PCOS, and ongoing product innovations by key players are contributing to the growth of the polycystic ovarian syndrome (PCOS) treatment market in North America. According to the US Department of Health & Human Services, PCOS is a common cause of female infertility in the US, affecting approximately 6% to 12% (around 5 million) of women of reproductive age. A study published in July 2023 in the American Journal of Obstetrics and Gynecology reported an incidence rate of 42.5 cases of PCOS per 10,000 people annually in the US. Additionally, various organizations in the country are dedicated to comprehensive evaluation, raising awareness, and focusing on research related to PCOS. For instance, the UCSF Center for Reproductive Health is actively involved in research to understand the causes of PCOS. Thus, the high prevalence of PCOS and the presence of organizations focused on research and awareness support the growth of the polycystic ovarian syndrome (PCOS) treatment market.

Polycystic Ovarian Syndrome (PCOS) Treatment Market Report Scope

Industry Developments and Future Opportunities:Several strategic developments by leading players in the polycystic ovarian syndrome (PCOS) treatment market, as reported in company press releases, are highlighted below:

In April 2023, Celmatix launched a new PCOS drug program, introducing its latest therapeutic initiative targeting melatonin receptors outside the central nervous system (CNS). This therapeutic approach aims to fill a significant market gap for effective first-line therapies for various women's health issues, starting with PCOS and potentially extending to endometriosis and menopausal symptoms.

In January 2022, Celmatix Inc. announced a milestone achievement in its five-year, multi-target collaboration with Evotec. Evotec and Bayer AG reached a milestone to advance a PCOS drug program focused on a novel drug target identified by Celmatix into the hit identification phase.

Competitive Landscape and Key Companies:Prominent companies profiled in the polycystic ovarian syndrome (PCOS) treatment market report include Sanofi SA, Merck KGaA, Novartis, Mylan, Takeda Pharmaceutical Company Ltd, Abbott, Teva Pharmaceuticals, Salix Pharmaceuticals Inc, AstraZeneca, and Pfizer Inc. These companies are dedicated to developing new technologies, enhancing existing products, and expanding their geographic reach to meet the increasing global consumer demand.

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 Market Definition, Assumptions and Limitations
  • 1.3 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights
  • 2.2 Market Attractiveness Analysis

3. Research Methodology

4. Polycystic Ovarian Syndrome (PCOS) Treatment Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis

5. Polycystic Ovarian Syndrome (PCOS) Treatment Market - Key Market Dynamics

  • 5.1 Key Market Drivers
  • 5.2 Key Market Restraints
  • 5.3 Key Market Opportunities
  • 5.4 Future Trends
  • 5.5 Impact Analysis of Drivers and Restraints

6. Polycystic Ovarian Syndrome (PCOS) Treatment Market - Global Market Analysis

  • 6.1 Polycystic Ovarian Syndrome (PCOS) Treatment - Global Market Overview
  • 6.2 Polycystic Ovarian Syndrome (PCOS) Treatment - Global Market and Forecast to 2031

7. Polycystic Ovarian Syndrome (PCOS) Treatment Market - Revenue Analysis (USD Million) - By Product, 2021-2031

  • 7.1 Overview
  • 7.2 Clomiphene Citrate
  • 7.3 Metformin
  • 7.4 Pioglitazone
  • 7.5 Oral Contraceptives
  • 7.6 Others

8. Polycystic Ovarian Syndrome (PCOS) Treatment Market - Revenue Analysis (USD Million) - By Distribution Channel, 2021-2031

  • 8.1 Overview
  • 8.2 Hospital Pharmacies
  • 8.3 Retail Pharmacies
  • 8.4 Online Pharmacies

9. Polycystic Ovarian Syndrome (PCOS) Treatment Market - Revenue Analysis (USD Million), 2021-2031 - Geographical Analysis

  • 9.1 North America
    • 9.1.1 North America Polycystic Ovarian Syndrome (PCOS) Treatment Market Overview
    • 9.1.2 North America Polycystic Ovarian Syndrome (PCOS) Treatment Market Revenue and Forecasts to 2031
    • 9.1.3 North America Polycystic Ovarian Syndrome (PCOS) Treatment Market Revenue and Forecasts and Analysis - By Product
    • 9.1.4 North America Polycystic Ovarian Syndrome (PCOS) Treatment Market Revenue and Forecasts and Analysis - By Distribution Channel
    • 9.1.5 North America Polycystic Ovarian Syndrome (PCOS) Treatment Market Revenue and Forecasts and Analysis - By Countries
      • 9.1.5.1 United States Polycystic Ovarian Syndrome (PCOS) Treatment Market
        • 9.1.5.1.1 United States Polycystic Ovarian Syndrome (PCOS) Treatment Market, by Product
        • 9.1.5.1.2 United States Polycystic Ovarian Syndrome (PCOS) Treatment Market, by Distribution Channel
      • 9.1.5.2 Canada Polycystic Ovarian Syndrome (PCOS) Treatment Market
        • 9.1.5.2.1 Canada Polycystic Ovarian Syndrome (PCOS) Treatment Market, by Product
        • 9.1.5.2.2 Canada Polycystic Ovarian Syndrome (PCOS) Treatment Market, by Distribution Channel
      • 9.1.5.3 Mexico Polycystic Ovarian Syndrome (PCOS) Treatment Market
        • 9.1.5.3.1 Mexico Polycystic Ovarian Syndrome (PCOS) Treatment Market, by Product
        • 9.1.5.3.2 Mexico Polycystic Ovarian Syndrome (PCOS) Treatment Market, by Distribution Channel
  • 9.2 Europe
    • 9.2.1 Germany
    • 9.2.2 France
    • 9.2.3 Italy
    • 9.2.4 Spain
    • 9.2.5 United Kingdom
    • 9.2.6 Rest of Europe
  • 9.3 Asia-Pacific
    • 9.3.1 Australia
    • 9.3.2 China
    • 9.3.3 India
    • 9.3.4 Japan
    • 9.3.5 South Korea
    • 9.3.6 Rest of Asia-Pacific
  • 9.4 Middle East and Africa
    • 9.4.1 South Africa
    • 9.4.2 Saudi Arabia
    • 9.4.3 U.A.E
    • 9.4.4 Rest of Middle East and Africa
  • 9.5 South and Central America
    • 9.5.1 Brazil
    • 9.5.2 Argentina
    • 9.5.3 Rest of South and Central America

10. Industry Landscape

  • 10.1 Mergers and Acquisitions
  • 10.2 Agreements, Collaborations, Joint Ventures
  • 10.3 New Product Launches
  • 10.4 Expansions and Other Strategic Developments

11. Competitive Landscape

  • 11.1 Heat Map Analysis by Key Players
  • 11.2 Company Positioning and Concentration

12. Polycystic Ovarian Syndrome (PCOS) Treatment Market - Key Company Profiles

  • 12.1 Sanofi SA
    • 12.1.1 Key Facts
    • 12.1.2 Business Description
    • 12.1.3 Products and Services
    • 12.1.4 Financial Overview
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Developments
  • 12.2 Merck KGaA
  • 12.3 Novartis
  • 12.4 Mylan
  • 12.5 Takeda Pharmaceutical Company Ltd
  • 12.6 Abbott
  • 12.7 Teva Pharmaceuticals
  • 12.8 Salix Pharmaceuticals
  • 12.9 AstraZeneca
  • 12.10 Pfizer Inc

13. Appendix

  • 13.1 Glossary
  • 13.2 About The Insight Partners
  • 13.3 Market Intelligence Cloud